Vendor Graveyard · Regulatory milestones

Ashraf et al. "Multifactor Quality and Safety Analysis of Semaglutide Products"

TitrateLab incident archive · J Med Internet Res, November 7, 2024

This is one entry from the TitrateLab Vendor Graveyard, a dated archive of peptide-market shutdowns, buyer-loss reports and enforcement actions. Documented as J Med Internet Res, November 7, 2024. Evidence tier: Official or peer-reviewed record. Sources for this entry are linked inline below and annotated in the full Vendor Graveyard entry.

A peer-reviewed study made six test purchases of semaglutide from online sellers that required no prescription. Three vials arrived and were analysed; the three prefilled pens never arrived. Measured purity was 7.7% to 14.37%, semaglutide content exceeded the labelled amount by 28.56% to 38.69%, and endotoxin was detected in all three samples at 2.1645 to 8.9511 EU/mg.

The study is by Ashraf, Mackey, Vida, Kulcsár, Schmidt, Balázs, Domián, Li, Csákó and Fittler, published November 7, 2024. Its sample is three vials, so it shows what those purchases contained, not how common such products are.

Correction, October 1, 2026. This entry previously credited the study to "Ambrus et al." in JMIR Infodemiology with doi 10.2196/52877, described seven samples, and called it the most-cited primary source in the field. The authors, journal, DOI and sample size were wrong, and the superlative was unsupported. The page moved from /research/graveyard/ambrus-semaglutide-analysis to /research/graveyard/ashraf-semaglutide-analysis.

Evidence tier: Official or peer-reviewed record.

Sources: J Med Internet Res 2024;26:e65440; PMC11582493; doi 10.2196/65440.

← Back to the full Vendor Graveyard
Dated shutdowns, buyer-loss reports and enforcement actions, 2020-2026, each with its evidence tier and sources.
Vendor and manufacturer names are used descriptively to identify parties in the documentary record; inclusion is not endorsement. Think a passage misrepresents the record? [email protected].